Molotinib medication guide for the treatment of myelofibrosis

Molotinib, trade nameOjjaara, is a new drug developed by GlaxoSmithKline and was officially approved for medical use in September 2023. The drug acts as an inhibitor of JAK1/JAK2 and activin A receptor type 1 (ACVR1), specifically for the treatment of patients with myelofibrosis and anemia. It is suitable for the treatment of moderate or high-risk myelofibrosis,including primaryMF or secondary MF [post-polycythemia vera (PV) and post-idiopathic thrombocythemia (ET)], bringing new treatment hope to such patients. To ensure the patient's therapeutic effect and medication safety, please strictly follow the doctor's instructions.

1. Medication methods and dosage recommendations

Molotinib is an oral medication in the form of tablets. The standard dosage frequency is once a day, and 200 mg needs to be taken each time. If the patient's liver function is severely impaired and reaches Child-Pugh class C, the recommended starting dose should be adjusted to 150 mg daily. In addition, patients should swallow the tablets whole and avoid cutting, crushing or chewing when taking the medicine.

2. Precautions when using

Patients should have regular blood tests before starting treatment with molotinib and during treatment so that doctors can evaluate the patient's physical condition and ensure the appropriateness of treatment. If a patient has an allergic reaction to any component of molotinib, he should stop taking the drug immediately and seek medical advice promptly. At the same time, taking this drug may increase the patient's risk of serious infections, heart disease, stroke, blood clots, and cancer. Therefore, patients with immune system problems, a history of chronic infections, cancer, heart disease, thrombotic liver disease, smoking, etc. must explain their health conditions to their doctor in detail before starting to take the drug.

3. Medication recommendations for specific groups of people

Molotinib may pose a potential risk to the fetus. Therefore, female patients who may become pregnant should take reliable contraceptive measures during the medication and within one week after stopping the medication. At the same time, since the drug may be passed through breast milk, lactating women should avoid breastfeeding during the medication and within one week after stopping the medication, and discuss a suitable infant feeding plan with their doctor.

4. Interactions between drugs

During the medication period, patients should provide their doctor with a detailed list of all medications they are taking, including but not limited to prescription drugs, over-the-counter drugs, various vitamins and herbal supplements, to prevent the risk of possible drug-drug interactions.

5. Storage methods of medicines

Molotinib should be stored at room temperature in its original bottle. To ensure dryness of the tablets, the desiccant packet from the packaging should remain in the bottle. After each use of the medicine, make sure the bottle cap is tightly closed to prevent moisture.

During the entire medication process, if patients feel any discomfort or have any questions about the medication, they should immediately contact their attending physician or pharmacist for consultation.